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ABSTRACT 
Introduction: Matrix metalloproteinases (MMPs) and tissue inhibitors of 
metalloproteinases (TIMPs) are involved in the progression of several tumors, 
including breast cancer. Our aim was to investigate the association of 
immunohistochemical expression of protein MMP-2, and -9 and tissue inhibitors 
TIMP-1,-2,-3 by tumoral cells in the process of angiogenesis and to define their relation 
with clinicopathological features for breast cancer. 
Methods: Immunohistochemical analysis of MMP-2,-9, TIMP-1,-2,-3, 
endoglin/CD105, estrogen receptor (ER), progesterone receptor (PR), and human 
epidermal growth factor receptor 2 (HER2) status was performed on 79 tissue samples 
of breast cancer with axillary lymph node dissection. 
Results: Statistically significant difference was found between mean age of patients 
and tissue inhibitors of metalloproteinase (TIMP-1) expression status (p=0.008), i.e., 
women with TIMP-1 negative tumors were on average younger (mean age 46.5) 
compared to women with TIMP-1 positive tumors (mean age 58.1); TIMP-2 expression 
status showed association with ER status (p=0.017), while TIMP-3 negative tumors 
were on average more frequently ER and PR negative (p=0.016; p=0.027). Status of 
protein expression of MMP-9 was associated with TIMP-1 protein expression status 
(p=0.033), i.e., breast cancers with overexpression of protein MMP-9 were more 
frequently TIMP-1 protein positive. 
Conclusion: Only TIMPs were associated with clinicopathological features for breast 
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cancer. TIMP-2 expression was associated with worse (TIMP-2 positive tumors were 
frequently ER-negative), while TIMP-3 expression in tumoral cells was associated with 
better clinicopathological features for breast cancer (TIMP-3 positive tumors were 
frequently ER and PR positive). 
Keywords: Breast cancer; matrix metalloproteinases; tissue inhibitors of 
metalloproteinases; angiogenesis; endoglin; immunohistochemistry 
<H1>INTRODUCTION 
Considering the fact that extracellular matrix (ECM) plays an important role in cancer 
progression and that matrix metalloproteinases (MMPs) are main molecules 
responsible for its remodeling, over the past years many studies have observed their 
influence to cancer progression. Since their discovery, there have been attempts to 
develop MMP inhibitor programs, especially for breast cancer, which as a multifactorial 
and heterogeneous disease is urging for more targeted and personalized therapy (1). 
MMPs are main regulators during several phases of angiogenic process, from 
deposition and remodeling of ECM components, to cell proliferation and migration (2). 
They contribute to angiogenesis either by degrading basement membranes or by 
promoting and maintaining the angiogenic phenotype (1,3). In breast cancer 
progression, particular importance was given to MMP-2 and MMP-9 due to their 
specificity for Collagen IV and possible implication in metastatic spread (4,5). 
Although the results of a large number of studies showed a correlation between high 
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levels of MMPs with more aggressive form of disease and shorter overall survival 
period (4,6,7), some studies reported conflicting results (8,9). 
The results are even more inconsistent when it is about the main tissue inhibitors of 
MMPs. TIMPs, as well as MMPs, are secreted by tumoral and stromal cells. Increased 
TIMP expression may also mean a stromal response to a tumor invasion, or may 
indicate a tissue response during the control of the activity of the MMP in maintaining 
the integrity of the ECM. TIMPs have an anti-MMP activity which is responsible for 
tumor suppression but can also stimulate growth or influence the apoptosis. The balance 
between anti-MMP and antiapoptotic effect on tumor growth may depend on the 
amount of bioavailable TIMP proteins in the tumor microcirculation. Due to their main 
biological role, it is expected that increased levels of TIMPs inhibit tumor invasion and 
formation of distant metastases and thus improve prognosis (10). However, elevated 
TIMP levels are reported in association with cancer progression and identified as poor 
prognostic indicators in several human tumor types, including breast cancer (11,12). 
Recent studies have found TIMP-1 serum levels enhanced in patients with triple-
negative breast cancer (TNBC) and associated with poor prognosis (12), while others 
suggest TIMP-2 as a novel biological therapy for TNBC (13). 
Having in mind all those facts, we aimed to investigate the possible association of 
immunohistochemical expression of protein MMP-2, MMP-9, TIMP-1, -2, and -3 by 
breast carcinoma cells with angiogenesis and to compare it with standard 
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clinicopathological features for breast cancer in Bosnian women. 
<H1>METHODS 
<H2>Clinicopathological data 
The biopsy samples of 79 patients with invasive breast cancer (IBC) were diagnosed at 
the Department of Pathology, School of Medicine, Sarajevo, Bosnia and Herzegovina. 
All patients with IBC underwent partial or total mastectomy with axillary lymph node 
dissection. Patients who received neoadjuvant chemotherapy or radiotherapy, or had 
distant metastases at the time of diagnosis were excluded from the study. 
Mean age of the patients at the time of diagnosis was 56.08 (range from 30 to 87). 
All clinicopathological data are summarized in Table 1. 
<H2>Immunohistochemical procedures 
Protein expression of MMP-2, MMP-9, TIMP-1, TIMP-2, TIMP-3, Endoglin (CD105), 
estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth 
factor receptor 2 (HER2) was determined by immunohistochemistry. All the tissue 
specimens of breast with IBC were fixed in 10% neutral formalin and embedded in 
paraffin. 
Briefly, four-micron-thick paraffin sections were mounted on poly-D-lysine coated 
slides and heated overnight at 60°C. The sections were deparaffinized in xylene, 
rehydrated in a decreasing series of ethanol solutions (100%, 90%, and 80%) for 5 
minutes each and washed 2 times in 0.05 mol/L phosphate-buffered saline (PBS) (pH 
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7.4). To enhance antigen retrieval the sections were pretreated in a water bath with Tris-
ethylenediaminetetraacetic acid (EDTA) buffer (pH 9.0) for 15 minutes at 95-97°C 
except for primary antibodies anti-CD105 and antiprogesterone receptor which slides 
were pretreated in the microwave oven in an EDTA buffer solution (pH 9.0) 3 times for 
5 minutes each (1000 W/s). Endogenous peroxidase activity was blocked by incubating 
the sections in 0.3% hydrogen peroxide (H2O2) in methanol for 10 minutes, and to 
reduce the nonspecific binding capacity of the tissue, slides were then washed in PBS 
2 times for 5 minutes at room temperature. Afterward the sections were incubated with 
one of the respective primary antibodies obtained from Leica Biosystems, Newcastle 
Ltd.: As mouse monoclonal: Anti-MMP2 (NCL-MMP2-507, clone 17B11, dilution 
1:50), anti-TIMP2 (NCL-TIMP2-487, clone 46E5, dilution 1:20), anti-TIMP3 (NCL-
TIMP3, clone 18D12b, dilution 1:30), and anti-CD105 (NCL-CD105, clone 4G11, 
dilution 1:50) and from DakoCytomation, Glostrup, Denmark: Polyclonal rabbit anti-
human MMP9 (code A0150, dilution 1:50,), as well as monoclonal mouse: Anti-human 
TIMP1 (code M7293, clone VT7, dilution 1:50), anti-human ER-α (code M7047, clone 
1D5, dilution 1:30), anti-human PgR (clone PgR 636, dilution 1:30), and also 
HercepTestTM (code K5204). The sections were washed 3 times in PBS (2 minutes 
each). As staining detection system it was used CSA II/HRP mouse (code K1497; Dako, 
Glostrup, Denmark) for MMP-2 and TIMP-3, CSA I rabbit (code K1501) and CSA 
II/HRP mouse (code K1497; Dako, Glostrup, Denmark) for MMP-9, as well as 
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EnVision Detection Kit (Dako, Glostrup, Denmark) for TIMP-1, TIMP-2, and CD105 
for 30 minutes. The slides were washed in PBS 3 times for 2 minutes, incubated with 
3.3’-diaminobenzidine solution (DAB; Dako, Cytomation Inc.) as chromogen for 10 
minutes at ambient temperature until the color reaction was revealed, then washed 3 
times in distilled water (5 minutes each). Finally, the sections were counter-stained with 
Mayer’s hematoxylin for 2 minutes, washed thoroughly in running tap water, 
dehydrated with ethanol, clarified in xylol and mounted with Eukitt. 
<H2>Immunohistochemical evaluation 
The evaluation of immunohistochemical staining was carried out blind to the patient’s 
data and pathological features. 
Estimation of protein expression of MMP, TIMP, ER, PR, and HER-2 in breast 
carcinoma cells, as well as estimation of CD105 positive newly formed blood vessels 
in tumor tissue, was performed by the semi-quantitative method. 
The staining intensity of protein MMP-2, MMP-9, TIMP-1, TIMP-2, and TIMP-3 and 
the number of stained tumor cells were both taken into consideration. Stains were 
scored on a scale of 0-3: Score 0, was assigned for no staining; score 1, if cytoplasm 
and cell membrane weakly stained in <10% tumor cells; score 2, for weak to moderate 
staining in 10-30% of tumor cells; score 3, if more than 30% of tumor cells strongly 
stained. The immunohistochemical expression was classified as positive or negative, 
considering 0 and 1 as negative and 2 or 3 as positive. Samples were considered to be 
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MMP-2, MMP-9, TIMP-1, TIMP-2, and TIMP-3 positive when ≥10% of tumor cells 
were immunoreactive. 
ER and PR positivity were defined as any positive nuclear staining (i.e., ≥1%) (14). 
HER-2 immunolabeling was measured according to the HercepTest scoring system 
(DakoCytomation) as follows: 0- no staining or faint incomplete membranous staining 
in <10% cells; 1- faint incomplete membranous staining in >10% cells, 2- weak to 
moderate complete staining in >10% cells, and 3- strong complete staining in >10% 
cells. Cases scored as 2+ were considered equivocal, and retested using chromogen in 
situ hybridization. 
<H2>Quantification of angiogenesis 
Sections stained with anti-CD105 antibody were used for the quantification of newly 
formed blood vessels in breast carcinoma tissue. The microscopic fields of breast 
carcinoma were observed by magnification ×200. Newly formed, CD105 positive blood 
vessels with visible vascular lumen were counted in 10 visual fields, separately. The 
total number of newly formed blood vessels was quantified as the mean value for each 
tumor sample and expressed as the total number of newly formed blood vessels by the 
high power field magnification. Isolated cells or vascular cells without visible lumen 
were not taken into account. 
<H2>Statistical analysis 
Statistical analysis was performed using SPSS version 21.0 (SPSS Inc., Chicago, IL). 
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Normality of the distribution of numerical variables was tested using Kolmogorov-
Smirnov, or Shapiro-Wilk test, where appropriate. Accordingly, all variables are 
presented by the appropriate measures of central tendency - arithmetic mean (± standard 
deviation) or median (with interquartile range). The values of categorical variables are 
presented in absolute numbers. T-test, Mann–Whitney U-test, and ANOVA (with 
Bonferroni multiple comparisons) were used to test the statistical significance in 
differences in respective central tendency measures of the numerical variables between 
sub-groups (according to clinicopathological features for breast cancer and the status 
of protein MMP-2, MMP-9, TIMP-1, TIMP-2, and TIMP-3). Chi-square test (or 
Fisher’s exact test, where appropriate) was used to test the dependence between 
individual categorical variables (i.e., clinicopathological features for breast cancer and 
the status of the tissue expression of MMP-2, MMP-9, TIMP-1, TIMP-2, and TIMP-
3). P=0.05 or less was considered statistically significant for all statistical analyses. 
<H1>RESULTS 
Protein expression of MMP-2, MMP-9, TIMP-1, TIMP-2, and TIMP-3 in breast cancer 
tissue. 
MMP-2, MMP-9, TIMP-1, TIMP-2, and TIMP-3 proteins were mainly expressed in the 
cytoplasm or membranes of tumor cells, as well as protein CD105/Endoglin in 
endothelial cells of newly formed blood vessels of breast cancer tissue (Figure 1). 
The expression of MMPs (MMP-2, MMP-9), tissue inhibitors of MMPs (TIMP-1, 
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TIMP-2, and TIMP-3) in cancer cells, and the mean number of CD105 newly formed 
blood vessels were observed in relation to the distribution of clinicopathological 
features for breast cancer. 
Relationship between MMP protein expression in breast cancer tissue and 
clinicopathological features. Protein expression of MMP-2 and MMP-9 in breast 
cancer cells showed no relation to patients age, tumor size, tumor grade, 
lymphovascular invasion, lymph node status, nor to ER, PR status, and HER2 status 
(Table 2). 
Relationship between TIMP protein expression in breast cancer tissue and 
clinicopathological features. Statistically significant difference in mean age of 
patients was found to exist with respect to TIMP-1 expression status (p=0.008), i.e., 
women with TIMP-1 negative expression were on average younger (mean age 46.5) 
compared to women with TIMP-1 positive expression (mean age 58.1). TIMP-1 
expression status showed association with patients’ age group (<50 or ≥50 years), i.e., 
patients aged ≥50 were on average more frequently TIMP-1 positive (p=0.000), while 
to other clinicopathological features showed no relation. 
TIMP-2 expression status was associated with ER status (p=0.017), i.e., TIMP-2 
positive tumors were on average more frequently ER-negative, while TIMP-2 negative 
tumors were more frequently ER-positive (Table 2). 
TIMP-3 expression status showed association with estrogen and progesterone receptor 
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status; TIMP-3 negative tumors were on average more frequently ER and PR negative 
(p=0.016 and p=0.027, respectively) (Table 2). 
Relationship between mean number of CD105 newly formed blood vessels in 
breast cancer tissue and clinicopathological features. Statistically significant 
difference in a mean number of CD105 newly formed blood vessels, and tumor size 
(pT) was found to exist (between pT1 and pT2, p=0.017) (Table 2). 
Regarding the tumor grade (G), statistically significant difference in a mean number of 
CD105 newly formed blood vessels was shown to exist between tumors of G1 and G2 
(p=0.002), and between tumors of G1 and G3 (p=0.002) (Table 2). 
The mean number of newly formed blood vessels was higher in ER-negative and PR 
negative tumors (compared to ER and PR positive tumors), (p=0.002, and p=0.006, 
respectively). 
Relationship between MMP, TIMP protein expression and CD105 newly formed 
blood vessels. An analysis of MMPs and TIMPs tissue expression revealed a significant 
association only between MMP-9 and TIMP-1. As shown in Table 3, status of tissue 
expression of MMP-9 was associated with TIMP-1 tissue expression status (p=0.033). 
We found that breast cancers with overexpression of protein MMP-9 were more 
frequently TIMP-1 protein positive. However, no statistically significant difference in 
mean number of CD105 newly formed blood vessels was found to exist between 
different groups with respect to MMPs and TIMPs expression status. 
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<H1>DISCUSSION 
The development of metastases is a complex process involving angiogenesis and 
degradation of ECM, which are essential for the spread and proliferation of cancer cells. 
These events include the activity of MMPs and their tissue inhibitors (TIMPs) which 
seem to be involved in the propagation of various tumors, including breast cancer 
(3,15). The expression of MMPs is generally very low and mainly regulated by 
transcription. Other mechanisms of their regulation include post-translational 
modification, latent-zymogen forms of MMPs and coexpression of TIMPs. Many 
members of MMP family are dysregulated in human cancers, especially MMP-1, -2, -
7, -9, and 13 (1). In a variety of studies related to MMPs and TIMPs in breast cancer, 
different methods of assessment were used, including immunohistochemistry, gene 
expression, its activity in serum or plasma, or expression by mRNA in situ hybridization 
with the sole purpose to target them as diagnostic and therapeutic molecules in breast 
cancer (16). 
In this study, we evaluated the significance of immunohistochemical expression of 
protein MMP-2, and -9 and their tissue inhibitors TIMP-1,-2, and -3 by tumoral cells in 
the process of angiogenesis, by comparing it with well-established clinicopathological 
features for breast carcinoma. The advantages of immunohistochemical evaluation are 
the direct readout of protein levels and the possibility to distinguish the expression of 
examined proteins in tumor versus stromal cells (16). 
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Immunohistochemical expression of MMP-2 protein was positive in 64.56% of cancer 
cells, and MMP-9 protein in 92.41%. MMP-2 and MMP-9 status showed no association 
with clinicopathological features for breast cancer (Table 2). 
Using immunohistochemistry, Vizoso et al., (17), Li et al. (18), and Talvensaari-Mattila 
et al. (19) reported opposite results in their studies, i.e., that the expression of 
metalloproteinases is related to poor prognosis in breast cancer patients. Pellikainen et 
al. in the study of 421 patients found high MMP-9 expression in stromal cells to be 
prognostic for poor recurrence-free survival and breast cancer specific survival, while 
MMP-9 expression in tumoral cells was associated with smaller tumors and better 
survival outcomes in this cohort (20). Scorilas and colleges found that lower expression 
of MMP-9 by tumoral cells is associated with poor prognostic factors, i.e., with tumors 
of greater diameter (8). 
No statistically significant difference in the mean number of CD105 newly formed 
blood vessels was found to exist between different groups with respect to MMP-2 and 
MMP-9 (Table 3), although the higher number of CD105 positive newly formed blood 
vessels was recorded in MMP-2 and MMP-9 positive tumors (p>0.05). 
In general, TIMPs are known for their ability to inhibit MMP activity, but recently 
many MMP-independent functions of TIMPs have been discovered, thus highlighting 
their dual role in cell-ECM interactions and tumor behavior (21). 
TIMPs are able to inhibit all active MMPs, but not with the same efficacy. TIMP-1 
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mostly inhibits MMP-7, MMP-9, MMP-1, and MMP-3, while TIMP-2 is the most 
effective inhibitor of MMP-2. TIMP-3 can inhibit MMP-2 and MMP-9 (22). In our 
study, status of tissue expression of MMP-9 was associated with TIMP-1 tissue 
expression status (p=0.033) (Table 3), which was expected due to previously mentioned 
facts. Jinga et al. pointed to the possibility that imbalance between MMP-9 and TIMP-
1 can be involved in the development of invasive breast carcinoma (4). By contrast, 
Thorsen et al., in a large study of 465 breast cancer patients examining the plasma 
concentration of MMP-9/TIMP-1 complex, found no correlation with disease-free 
survival (23). High serum and tumor levels of TIMP-1 have been reported in association 
with poor response to chemotherapy and decreased survival (24,25). Our results 
showed statistically significant difference in mean age of patients with respect to TIMP-
1 expression status (i.e., between groups with positive and negative expression of 
TIMP-1) (p= 0.008). Women with TIMP-1 negative expression were on average 
younger (mean age 46.5) compared to women with TIMP-1 positive expression (mean 
age 58.1). TIMP-1 expression status showed association with patients’ age group (<50 
or ≥50 years), i.e., patients aged ≥50 were on average more frequently TIMP-1 positive 
(p=0.000) (Table 2). 
TIMP-2 expression status showed association with ER status (p=0.017), i.e., TIMP-2 
positive tumors were on average more frequently ER-negative, while TIMP-2 negative 
tumors were more frequently ER-positive (Table 2). Same results showed other studies 
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(11,26) once again indicating to the relation between TIMP-2 and aggressive behavior 
of breast cancer. 
Among all TIMPs, TIMP-3 has the broadest spectrum of inhibition, and unlike others, 
TIMP-3 is tightly bounded to ECM (27). TIMP-3 expression status was associated with 
estrogen and progesterone receptor status; TIMP-3 positive tumors were on average 
more frequently ER and PR positive (p=0.016 and p=0.027, respectively) (Table 2). 
Measuring mRNA levels of TIMPs, Span et al. reported TIMP-3 as an only possible 
predictor for relapse-free survival in breast cancer patients, i.e., breast cancers with high 
TIMP-3 expression showed a better response to endocrine therapy (28). Likewise, 
Vizoso et al. have reported significantly higher TIMP-3 expression in ER-positive 
tumors. They also found that TIMP-3 expression by fibroblastic cells, but not by 
tumoral cells correlates positively with distant metastases (17). 
We also investigated possible differences in angiogenesis, i.e., the mean number of 
CD105 positive newly formed blood vessels with regard to standard clinicopathological 
features for breast carcinoma. Statistically significant difference was observed in mean 
number of CD105 newly formed blood vessels between tumors of G1 and G2 
(p=0.002), and between tumors of G1 and G3 (p=0.002) (Table 2), i.e., tumors of Grade 
2 had on average more CD105 positive newly formed blood vessels compared to Grade 
1 tumors as well as tumors of Grade 3 compared to Grade 1 tumors. An increase in the 
number of newly formed blood vessels was observed with increasing of tumor size, 
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although statistically significant difference was found to exist only between tumors of 
pT1 and pT2 (p=0.017) (Table 2), showing that tumors larger than 2 cm need more 
blood supply for progression. The mean number of newly formed blood vessels was 
higher in ER-negative and PR-negative tumors (compared to ER and PR positive 
tumors), (p=0.002, and p=0.006, respectively), which confirmed the findings of 
previous studies and also indicate that ER and PR negative tumors are associated with 
more aggressive clinical behavior, higher histological grade and negative 
clinicopathological features for breast carcinoma (29). 
<H1>CONCLUSIONS 
To our best knowledge, this is the first study involving MMPs and TIMPs in breast 
cancer of Bosnian women. When it comes to tissue inhibitors of MMPs our results 
especially highlight the complex role of TIMPs in cancer progression as well as the 
complexity of TIMP-MMP interaction. In support of that are findings that some of 
TIMPs were associated with worse (i.e., TIMP-2) and some with a better pathological 
prognostic-predictive factor for breast carcinoma (i.e., TIMP-3), as well as the existence 
of MMP-TIMP dependency (i.e., MMP-9 and TIMP-1). Results of our study do not 
indicate a significant association of MMPs with angiogenesis (mean number of CD105 
newly formed blood vessels) nor with clinicopathological features for breast cancer. 
Possible reasons for that could be relatively small sample size, ethnic differences, the 
usage of different antibodies or laboratory procedures compared to previous studies and 
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the fact that we assessed the protein expression only in tumoral cells. Further studies, 
especially prospective ones, with greater sample size and the usage of different methods 
to asses MMPs and TIMPs in breast cancer, will be necessary to determine the impact 
of MMPs and TIMPs to progression and outcome in Bosnian women. 
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Figures 
 
FIGURE 1. Immunohistochemical staining of proteins matrix metalloproteinases 
(MMP-2), MMP-9, tissue inhibitors of metalloproteinases (TIMP-1), TIMP-2 and 
TIMP-3 in the cytoplasm and membranes of breast cancer cells. CD105/Endoglin 
positive newly formed blood vessels in the invasive breast cancer tissue, lined by a 
single layer of immunopositive flattened endothelial cells with a visible vascular lumen.
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Tables 
TABLE 1. Clinicopathological characteristics of 79 studied cases with primary breast 
carcinoma 
Variables n (%) 
Age groups  
<50 19 (24.05) 
>50 60 (75.95) 
Histological type  
Ductal 71 (89.87) 
Lobular 8 (10.13) 
Tumor grade (G)  
G1 15 (18.99) 
G2 38 (48.10) 
G3 26 (32.91) 
Tumor size (pT)  
pT1 26 (32.91) 
pT2 41 (51.90) 
pT3 9 (11.39) 
pT4 3 (3.80) 
Nodal status  
Negative 35 (44.30) 
Positive 44 (55.70) 
Lymphovascular  
Absent 37 (46.84) 
Present 42 (53.16) 
Invasion (lvi)  
Negative 29 (36.71) 
Positive 50 (63.29) 
ER status  
 - 23 - 
Negative 33 (41.77) 
Positive 46 (58.23) 
PR status  
0 43 (54.43) 
1+ 15 (18.99) 
2+ 8 (10.13) 
3+ 13 (16.45) 
HER2 expression  
Negative 58 (73.42) 
Positive 21 (26.58) 
MMP-2 expression  
Negative 28 (35.44) 
Positive 51 (64.56) 
MMP-9 expression  
Negative 6 (7.59) 
Positive 73 (92.41) 
TIMP-1 expression  
Negative 20 (25.32) 
Positive 59 (74.68) 
TIMP-2 expression  
Negative 63 (79.75) 
Positive 16 (20.25) 
TIMP-3 expression  
Negative 4 (5.06) 
Positive 75 (94.94) 
ER: Estrogen receptor, PR: Progesterone receptor, HER2: Human epidermal growth 
factor receptor-2, MMP-2: Matrix metalloproteinase-2, MMP-9: Matrix 
metalloproteinase-9, TIMP-1: Tissue inhibitor, of matrix metalloproteinase-1, TIMP-2: 
Tissue inhibitor of matrix metalloproteinase-2, TIMP-3: Tissue inhibitor of matrix 
metalloproteinase-3 
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TABLE 2. Distribution of clinicopathological parameters for breast cancer in relation to the status of the tissue expression of MMP-2, MMP-9, TIMP-1, TIMP-2, 
TIMP-3 and the number of CD105 positive newly formed blood vessels 
Clinicopathological 
parameters/prognostic-
predictive factors 
MMP 2 MMP9 TIMP1 TIMP2 TIMP3 CD105 
Age Positive Negative Positive Negative Positive Negative Positive Negative Positive Negative  
(x SD)  55.5±11.9 57.3±12.2 56.1±11.9 56.2±13.5 58.1±11.1 46.5±15.0 
p=0.008 
56.9±9.7 55.9±12.5 56.4±12.0 54.5±15.0 N/A 
Age group            
<50 13 6 17 2 8 11 2 17 18 1 12.3±4.9 
>50 8 22 56 4 51 9 
p=0.000 
14 46 57 3 13.3 
(10.3) 
Tumor size            
pT1 16 10 25 1 22 4 6 20 24 2 9.5±5.6 
pT2 26 15 38 3 29 12 8 33 41 0 13.5 
(10.0) 
pT3 6 3 8 1 6 3 1 8 7 2 11.3 
(10.4) 
pT4 3 0 2 1 2 1 1 2 3 0 19.8±3.9 
p=0.017 
Histological grade            
G1 8 7 15 0 12 3 2 13 14 1 6.4±3.6 
G2 26 12 35 3 31 7 8 30 37 1 14.2 (9.7) 
G3 17 9 23 3 16 10 6 20 24 2 13.4 (9.0) 
p=0.002 
Lymphovascular 
invasion 
           
Present 31 11 37 5 31 11 9 33 40 2 13.0 (9.4) 
Absent 20 17 36 1 28 9 7 30 35 2 12.7 
(11.0) 
Lymph node status            
Positive 28 16 40 4 31 13 10 34 43 1 13.1 (9.2) 
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Negative 23 12 33 2 28 7 6 29 32 3 10.0 
(11.9) 
Status of estrogen 
receptors 
           
Positive 30 20 46 4 40 10 6 44 50 0 10.9±5.9 
Negative 21 8 27 2 19 10 10 19 
p=0.017 
25 4 
p=0.016 
16.2 (9.4) 
p=0.002 
Status of progesterone 
receptors 
           
Positive 32 14 43 3 36 10 7 9 46 0 11.1±5.8 
Negative 19 14 30 3 23 10 39 24 29 4 
p=0.027 
14.1 
(13.1) 
p=0.006 
HER2 expression            
0 26 17 13 0 32 11 4 39 41 2 13.2 (9.4) 
1+ 10 5 7 1 12 3 5 10 15 0 11.3±6.9 
2+ 4 4 12 3 6 2 2 6 8 0 15.8±8.3 
3+ 11 2 41 2 9 4 5 8 11 2 13.0 (8.8) 
Status of HER2 
expression 
           
Positive 15 6 20 1 15 6 7 14 19 2 13.1 
(12.3) 
Negative 36 22 53 5 44 14 9 49 56 2 12.7±7.8 
MMP-2: Matrix metalloproteinase-2, MMP-9: Matrix metalloproteinase-9, TIMP-1: Tissue inhibitor of matrix metalloproteinase-1, TIMP-2: Tissue inhibitor of 
matrix metalloproteinase-2, TIMP-3: Tissue inhibitor of matrix metalloproteinase-3, HER-2: Human epidermal growth factor receptor-2, N/A: Not applicable 
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TABLE 3. Distribution of matrix metalloproteinases, tissue inhibitors of metalloproteinases, and number of CD105 newly formed blood vessels 
??? MMP-2 MMP-9 TIMP-1 TIMP-2 TIMP-3 CD105 
Positive Negative Positive Negative Positive Negative Positive Negative Positive Negative  
MMP-2            
Positive 
N/A 
46 5 39 12 10 41 47 4 13.0 (9.3) 
Negative 27 1 20 8 6 22 28 0 12.3 (11.7) 
MMP-9            
Positive 46 27 
N/A 
57 16 16 57 49 4 13.0 (9.3) 
Negative 5 1 2 4 
p=0.033 
0 6 6 0 11.4±7.6 
TIMP-1            
Positive 39 20 57 2 
N/A 
12 47 55 4 13.0 (9.2) 
Negative 12 8 16 4 
p=0.033 
4 16 20 0 12.9±7.5 
TIMP-2            
Positive 10 6 16 0 12 4 
N/A 
15 1 13.3 (12.9) 
Negative 41 22 57 6 47 16 60 3 17.4±12.8 
TIMP-3            
Positive 47 28 69 6 55 20 15 60 
N/A 
12.8 (9.4) 
Negative 4 0 4 0 4 0 1 3 12.6±3.9 
MMP-2: Matrix metalloproteinase-2, MMP-9: Matrix metalloproteinase-9, TIMP-1: Tissue inhibitor of matrix metalloproteinase-1, TIMP-2: Tissue inhibitor of 
matrix metalloproteinase-2, TIMP-3: Tissue inhibitor of matrix metalloproteinase-3, N/A: Not applicable 
 
